4 completed, 3 withdrawn, 1 terminated. 8 Phase 1, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 8 | Completed 4, Withdrawn 3, Terminated 1 |
| Phase 2 | 4 | Withdrawn 2, Completed 1, Terminated 1 |
Follow BGJ398: new trials by email Literature Review of BGJ398 trials Research Report on BGJ398
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 Alterations Infigratinib - Advanced Solid Tumor, CNS Tumor | Phase 1 / Phase 2 | Withdrawn | Helsinn Healthcare SA | 2021-10-01 | 2023-02-23 | |
| Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer Infigratinib, Quality-of-Life Assessment, Questionnaire Administration - Renal Pelvis and Ureter Urothelial Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 15 | 2020-07-28 | 2025-01-01 |
| Ph Ib/BGJ398/Cervix and Other Solid Tumors BGJ398, Carboplatin, Paclitaxel - Cancer of Cervix, Tumors | Phase 1 | Withdrawn | The University of Texas Health Science Center at San Antonio | 2015-01-01 | 2015-02-16 | |
| BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST) BGJ398, Imatinib Mesylate - Advanced Gastrointestinal Stromal Tumor (GIST) | Phase 1 / Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 16 | 2014-10-02 | 2020-03-30 |
| Phase 1b Trial of BGJ398/BYL719 in Solid Tumors BGJ398, BYL719 - Advanced Solid Tumors, Metastatic Solid Tumors | Phase 1 | Completed | Novartis Pharmaceuticals | 62 | 2013-10-01 | 2020-12-09 |
| A Phase I Study of Oral BGJ398 in Asian Patients BGJ398 - Tumor With Alterations of the FGF-R | Phase 1 | Completed | Novartis Pharmaceuticals | 9 | 2012-10-19 | 2020-12-08 |
| A Dose Escalation Study in Adult Patients With Advanced Solid Malignancies BGJ398 - Advanced Solid Tumors With Alterations of FGFR1, 2 and or 3, Squamous Lung Cancer With FGFR1 Amplification | Phase 1 | Completed | Novartis Pharmaceuticals | 208 | 2009-12-11 | 2019-10-04 |
| Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer Fluorouracil, Irinotecan Hydrochloride, Laboratory Biomarker Analysis - Colon Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Withdrawn | Roswell Park Cancer Institute | 2016-05-20 |
Acrocephalosyndactylia (1) · Breast Neoplasms (1) · Central Nervous System Neoplasms (1) · Colonic Neoplasms (1) · Lung Neoplasms (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Rectal Neoplasms (1) · Urinary Bladder Neoplasms (1) · Uterine Cervical Neoplasms (1)
Novartis Pharmaceuticals (3) · Helsinn Healthcare SA (1) · M.D. Anderson Cancer Center (1) · Memorial Sloan Kettering Cancer Center (1) · Roswell Park Cancer Institute (1) · The University of Texas Health Science Center at San Antonio (1)
United States (6) · Germany (3) · Australia (2) · Canada (2) · France (2) · Italy (2) · Netherlands (2) · Singapore (2) · South Korea (2) · Spain (2) · Austria (1) · Belgium (1) · China (1) · Israel (1) · Japan (1)
Mehrad Adibi, MD (1) · Steven Weitman, MD (1) · Wen Wee Ma (1) · William Tap, MD (1)
2009 (1), P30CA016056 (1)